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Abstract
Background
Given the potentially causal association of female genital schistosomiasis (FGS) with HIV-1
infection, improved diagnostics are urgently needed to scale-up FGS surveillance. The BIL-
HIV (bilharzia and HIV) study assessed the performance of home-based self-collection
methods (cervical and vaginal swabs) compared to cervicovaginal lavage (CVL) for the
detection of Schistosoma DNA by real-time polymerase chain reaction (PCR).
Methods
Between January and August 2018, a consecutive series of female participants from the
Population-Cohort of the previous HIV prevention trial HPTN 071 (PopART), resident in Liv-
ingstone, Zambia were invited to take part in BILHIV if they were 18–31 years old, non-preg-
nant and sexually active. Genital self-collected swabs and a urine specimen were obtained
and a questionnaire completed at home visits. CVL was obtained at clinic follow-up.
Results
603 women self-collected genital swabs. Of these, 527 women had CVL performed by a
mid-wife during clinic follow-up. Schistosoma DNA was more frequently detected in genital
self-collected specimens (24/603, 4.0%) compared to CVL (14/527, 2.7%). Overall, 5.0%
(30/603) women had female genital schistosomiasis, defined as a positive PCR by any geni-
tal sampling method (cervical swab PCR, vaginal swab PCR, or CVL PCR) and 95% (573/
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603) did not have a positive genital PCR. The sensitivity of any positive genital self-collected
swab against CVL was 57.1% (95% CI 28.9–82.3%), specificity 97.3% (95.5–98.5%). In a
subset of participants with active schistosome infection, determined by detectable urine Cir-
culating Anodic Antigen (CAA) (15.1%, 91/601), positive PCR (4.3%, 26/601), or positive
microscopy (5.5%, 33/603), the sensitivity of any positive self-collected specimen against
CVL was 88.9% (51.8–99.7%).
Conclusions
Genital self-sampling increased the overall number of PCR-based FGS diagnoses in a field
setting, compared with CVL. Home-based sampling may represent a scalable alternative
method for FGS community-based diagnosis in endemic resource limited settings.
Author summary
Female Genital schistosomiasis (FGS) is a neglected and disabling disease that results
when eggs from the waterborne parasite Schistosoma haematobium are trapped in the
human reproductive tract. Current female genital schistosomiasis (FGS) diagnostic strate-
gies are limited because they require expertise and equipment that may not be readily
available in low income settings. Improved and accessible diagnostics are urgently needed
to scale-up FGS surveillance. This is especially important as FGS has been associated with
HIV-1 infection. The BILHIV (bilharzia and HIV) study assessed the performance of
home-based self-collection methods (cervical and vaginal swabs) compared with a clinic-
based cervicovaginal lavage (CVL) performed by a medical professional. Both methods
used real-time polymerase chain reaction (PCR) to detect Schistosoma DNA. We found
that, in a field setting, self-collected genital and cervical swabs increased the overall num-
ber of PCR-based FGS diagnoses, compared with clinically collected CVL. We report the
sensitivity of self-collected swabs for the diagnosis of FGS, compared with CVL. We found
that the sensitivity of self-collected genital swabs was high in a subset of women with
active schistosome infection. We suggest that home-based self-sampling may represent a
scalable community-based sampling platform for FGS community-based diagnosis in
endemic resource limited settings.
Introduction
An estimated 82 million women in sub-Saharan Africa live with Schistosoma (S.) haematobium
or S. mansoni infections [1] that follow fresh water contact. In Zambia alone, it is estimated
that 3.8 million people (approximately 22% of the population) are infected with Schistosoma
species [2]. After maturation, these trematode parasites commence egg-laying in the host’s
venous system and disease occurs when tissue-entrapped eggs cause both local and systemic
pathology [3]. Female genital schistosomiasis (FGS), defined as the detection of eggs or Schisto-
soma spp. DNA in genital tissue or fluids [4], affects an estimated 20–56 million women world-
wide [5], mostly in sub-Saharan Africa, including Zambia [6]. The presence of eggs or
Schistosoma spp. DNA in urine and stool does not confirm concurrent genital involvement [7,
8].
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Egg deposition in FGS occurs in clusters [9], often at the squamocolumnar junction in the
subepithelial connective tissue [9] and is therefore frequently missed on superficial Papanico-
laou-smear based sampling [8–10]. Often tissue-lodged eggs are accompanied by characteristic
sandy patches (both grainy and homogenous) [11] and rubbery papules [12]. However, in up
to one-quarter of cases, FGS occurs in macroscopically normal appearing cervical tissue [9,
13]. Classically, FGS lesions are visualized colposcopically [8, 12], requiring equipment and
trained clinical expertise that may not be available in low income settings [4]. Also, concern
that tissue biopsy, the proposed reference standard, may provide a means of entry for HIV-1
infection [4] has limited its use in FGS research. Given this theoretical risk, the use of polymer-
ase chain reaction (PCR) on cervicovaginal lavage (CVL) has been advocated as an acceptable
and less-invasive method of FGS diagnosis in research settings [8, 12, 14, 15]. However,
because CVL sampling requires a trained health professional, vaginal speculum insertion, and
an intact cold chain, it is not likely scalable for population–based FGS surveillance.
FGS has been associated with adverse reproductive health outcomes, such as infertility [16],
ectopic pregnancy [17, 18], and abortion [17]. Eggs deposited in reproductive tissues release
immunogenic antigens [19], resulting in granulomatous reaction and fibrosis [18]. There is
also increasing evidence on the association of FGS with prevalent HIV-1 infection [10, 20], a
relationship that may be causal. Accurate, accessible, and affordable diagnostics are urgently
needed to scale-up FGS surveillance and treatment. Schistosome infection is associated with a
continuum of disease co-morbidities and post-infection complications [21]. FGS can occur
along this continuum and there is currently not a diagnostic test that captures the entire range
of FGS clinical presentations [21].
Self-sampling has been used for diagnosis of reproductive tract infections, including
human papillomavirus (HPV) [22]. Compared with clinician collected specimens, self-col-
lected PCR-based HPV testing is acceptable to participants [23], increases screening coverage
[22, 24], and is as sensitive as clinician collected samples [25]. A home-based diagnostic option
for FGS with decreased reliance on medical professionals would have high field applicability.
This study was designed to compare the performance of two home-based self-collection meth-
ods (cervical and vaginal swabs), to clinic-based, midwife-collected CVL for the detection of
Schistosoma DNA by Nucleic Acid Amplification Tests (NAATs).
Methods
Study site and subjects
Between January and August 2018, participants from the Population Cohort (PC) of HPTN
071 (PopART), a trial to measure the impact of an HIV combination prevention package,
including universal HIV test and treat [26], were recruited to participate in the cross-sectional
bilharzia and HIV (BILHIV) study. Women were eligible to participate if they were 18–31
years old, non-pregnant, sexually active, and resident in one of the two communities (desig-
nated Community-A and Community-B) that participated in HPTN 071 (PopART) in Living-
stone, Zambia. Central Livingstone is located within 5–10 kilometres of the Zambezi River,
with a tributary flowing in close proximity to Community A. HPTN 071 (PopART) is a cluster
randomized trial including 21 participating communities. At the community level, the Popula-
tion Cohort included one randomly selected adult 18 to 44 years of age from a random sample
of households in each community [26]. BILHIV study participants were then selected as a con-
secutive sample from the HPTN 071 (PopART) Population Cohort. A 2013 survey of school
aged children in Livingstone reported prevalence ranges for urinary S. haematobium infection
between 3.3% and 73.3% (median 15.0%, mean 23.3%) [27].
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Home-based sample collection and questionnaire
Trained community workers provided home visits to women who gave an “expression of
interest” in the BILHIV study at the HPTN 071 (PopART) PC 36-month visit. The home visit
included assessment of eligibility, a questionnaire, genital self-sampling (cervical and vaginal),
and a single urine specimen. Trained field workers provided study information in the partici-
pant’s preferred language. Following written informed consent, a questionnaire containing
questions regarding demographics, water contact, sexual behaviour, and genital symptoms
was administered. There were no restrictions on the timing of urine sample self-collection,
and 69.5% (419/603) were performed between 9:00 and 14:00. The community worker pro-
vided participating women with instructions for urine collection and cervical and vaginal self-
sampling. Participants were instructed to hold a 6-inch PrimeSwab (Longhorn Diagnostics,
Texas, USA) at the 2 3/8-inch score mark, insert the swab vaginally until their fingers touched
the labia minora, and rotate the swab against the vaginal walls (minimum 15 repetitions) (Fig
1). Similarly, for the cervical swab, participants were instructed to hold a 6 3/4-inch flocked
swab (Miraclean, Shenzen, China) with a quadrilateral kite-shaped tip at the non-flocked end,
insert the swab until their fingers touched the labia minora and/or encountered resistance, and
rotate the swab against the place of resistance (minimum 15 repetitions). Each flocked swab
head was placed in individual screw cap microtubes (STARLAB, Hamburg, Germany) by the
participant after the swab shaft was broken. Both swab specimens and urine were placed in
cool boxes for transportation to the laboratory for further processing (see Supplementary
Material). Women with evidence of active schistosome infection, defined by any positive urine
examination (microscopy, Circulating Anodic Antigen (CAA) or PCR), or women with clini-
cal evidence of FGS as determined by the midwife’s clinical examination [28], were treated free
of charge with 40 mg/kg praziquantel, either at the clinic visit, or via community workers.
Fig 1. Genital Self-sampling in the BILHIV Study. A) Participants held a 6-inch vaginal swab at the 2 3/8-inch score
mark, inserted the swab vaginally until their fingers touched the labia minora, and rotated the swab against the vaginal
walls (minimum 15 repetitions). B) Participants held the 6 3/4-inch cervical swab at the non-flocked end, inserted the
swab until their fingers touched the labia minora and/or encountered resistance, and rotated the swab against the place
of resistance (minimum 15 repetitions).
https://doi.org/10.1371/journal.pntd.0008337.g001
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Clinic-based sample collection
Enrolled women who were not currently menstruating were invited to attend Livingstone
Central Hospital cervical cancer screening clinic within days of self-sampling, where one of
two trained midwives performed a cervicovaginal lavage (CVL). After speculum insertion,
normal saline (10mL) was flushed continuously with a bulb syringe across the cervix and vagi-
nal walls for one minute and collected from the posterior fornices. Images of the vagina and
cervix were captured with a point-of-care colposcope (MobileODT, Tel Aviv, Israel). Partici-
pants with suspected reproductive tract infections were offered syndromic management, as
per the Ministry of Health [29]. Routine testing for reproductive tract infections was not per-
formed in this study.
Laboratory analysis
Urine aliquoting for quantification of CAA, PCR, and urinalysis were performed on the day of
specimen arrival at the laboratory (see S1 Text). The remaining urine, up to 60mL per partici-
pant, was centrifuged in 15mL aliquots and examined by microscopy within 24 hours. The pel-
let from each 15mL urine aliquot (5 maximum) was evaluated for S. haematobium eggs. When
a pellet contained at least one terminal-spined ovum, the participant was considered positive
and the total number of counted eggs in the pellet was reported. Review of all positive and 10%
of the negative specimens was conducted blinded by an expert for quality control. Dipsticks
were used for analysis of hematuria and proteinuria (Multistix, Siemens, Germany). An up-
converting reporter particle (UCP) lateral flow (LF) assay for the quantification of CAA in
urine (0.4 mL) was performed at the Leiden University Medical Center (LUMC) (see S1 Text)
[30]. Urine CAA antigen levels are known to reflect adult worm burden and decline after suc-
cessful treatment with praziquantel [31, 32].
PCR for Schistosoma spp
Pre-treatment and DNA isolation of CVL, genital swabs, and urine samples were performed
(see S1 Text) in different sites at the LUMC, hence minor differences in the laboratory proce-
dures. Briefly, genital swabs were suspended in PBS and vortexed, and thereafter handled as
lavages, by pre-treating using a proteinase K heating step and isolating DNA using QIAamp
spin columns (QIAGEN Benelux, Venlo, The Netherlands) [8, 12, 33]. Two hundred μL of
urine sample per participant were pretreated using Precellys Soil grinding SK38 (Bertin tech-
nology, Montigny-le-Bretonneux, France) and DNA was isolated using MagNA Pure 96 tech-
nology (Roche Diagnostics, Penzberg, Germany). Internal transcribed spacer 2-based real-
time PCR was performed as previously described [33], with slight modifications (see S1 Text).
DNA amplification and detection were performed with the CFX96 Real Time PCR Detection
System (BioRad, California, USA). The output in threshold cycles (Ct) was analysed using
BioRad CFX software. Negative and positive control samples were included in each amplifica-
tion run. Parasite DNA load is categorized by the following pre-specified Ct threshold for all
specimens processed by PCR (urine, cervical swab, vaginal swab, and CVL): any Ct-value
observed means positive and no Ct-value observed means negative (S1 Text) [34]. All speci-
mens tested by PCR at LUMC were blinded for clinical and microscopy data.
Ethical considerations
The study was approved by the University of Zambia Biomedical Research Ethics Committee
(reference 011-08-17), the Zambia National Health Research Authority and the London School
of Hygiene and Tropical Medicine Ethics Committee (reference 14506). Permission to
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conduct the study was given by Livingstone District health office and the superintendent of
Livingstone Central Hospital. All the human subjects in this study were adults.
Statistical methods
We anticipated that the prevalence of S. haematobium infection would be 30% and that PCR
performed on self-collected specimens would have sensitivity of 70% and specificity of 85%.
Under these assumptions a sample size of 600 women would allow us to detect these target val-
ues with 95% confidence intervals of 63%-77% and 81%-88%, respectively.
Data were entered on hand-held electronic data capture devices using Open Data Kit and
analysed using STATA 15.1 (Stata Corporation, College Station, TX). Continuous variables
were summarized by median and interquartile range (IQR), and categorical variables by fre-
quency and percentage. Differences in participant characteristics between the two communi-
ties were evaluated using Fisher’s exact, chi-squared, and Wilcoxon-Mann-Whitney tests. The
association between age group and positive test result was assessed using the test for trend. For
the comparison of home-based self-collection methods with clinic based CVL, we calculated
sensitivity and specificity. There weren’t indeterminate PCR results or missing data for genital
self-collected swabs (the index test). “Definite” FGS was defined as any positive genital PCR
(cervical swab, vaginal swab or CVL). The presence of either CAA or S. haematobium eggs in
clinical specimens indicates the presence of infection with viable worms [30]. Thus, in this
study, “active” schistosome infection refers to participants with a positive urine PCR, CAA, or
microscopy. To evaluate if sequential use of FGS diagnostics might be beneficial, an ad-hoc
secondary analysis was performed in which calculation of the diagnostic performance was
restricted to those with an active schistosome infection according to positive urine PCR, CAA,
or microscopy. CVL was chosen as the a priori reference standard for the BILHIV study. In the
absence of a universally recognized reference standard for FGS, a composite FGS outcome was
constructed, defined as a positive result on any genital PCR specimen (swab or CVL).
Results
Overall, 1105 women in the study communities from the HPTN 071 (PopART) Population
Cohort met the inclusion criteria. A total of 603 (54.5%) eligible women were enrolled with
527 (87.0%) completing clinic follow up (Fig 2). Women from both communities reported reg-
ular water contact in childhood (p = 0.22) (Table 1). Overall, an active schistosome infection
was diagnosed in 15.6% (94/601) (Table 2), of which 33 were urine microscopy positive and an
additional 61 cases were diagnosed by urine CAA. Urine PCR confirmed the presence of schis-
tosome infection in 26 participants and did not detect any additional cases. Overall, 15.6% (94/
601) had schistosome infection (Table 2). The prevalence of S. haematobium infection was
5.5% (33/603) based on urine microscopy, 15.1% (91/601) by urine CAA, and 4.3% (26/601)
by urine PCR (Table 2).
There were 30 women (5.0%) with definite FGS, defined as any positive genital PCR (cervi-
cal swab, vaginal swab or CVL), 22/291 (7.6%) in Community-A and 8/238 (3.4%) in Commu-
nity-B (p = 0.04) and 95% (573/603) did not have definite FGS. The proportion of participants
testing positive decreased with increasing age for all tests except urine CAA and CVL PCR
(urine microscopy p-trend = 0.004, urine PCR p-trend = 0.003, any PCR-positive genital speci-
men p-trend<0.001, cervical swab PCR p-trend<0.001, vaginal swab PCR p-trend<0.001)
(Fig 3 & S1 Table). In the 30 women with FGS, the prevalence of active schistosome infection
was 70.0% (21/30). Of the 94 women with an active schistosome infection, 22.3% (21/94) had
FGS and of the 507 women without active schistosome infection 1.8% (9/507) had FGS
(p<0.001), these numbers include women who did not attend clinic follow-up. Fig 4 illustrates
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FGS diagnosis based on PCR positivity for each of the three genital sampling methods. No
adverse events were reported in either group related to use of the index or reference test.
The sensitivity of a positive result from any positive self-collected specimen (cervical or vag-
inal swab) against CVL was 57.1% (28.9–82.3) with specificity of 97.3% (95.5–98.5%)
(Table 3). Compared with CVL, the sensitivity of self-collected cervical swabs (42.9% [17.7–
71.1%]) was somewhat higher than for vaginal swabs (35.7% [12.8–64.9]), albeit with wide
confidence intervals. The specificity of PCR in self-collected specimens versus CVL was high
regardless of sampling technique (cervical 97.7% [95.9–98.8%], vaginal 98.2% [96.7–99.2%])
(Table 3). Self-collected genital swabs were also evaluated as the reference standard (Table 3).
Of these comparisons, the highest sensitivity (80% [61.4–92.3] was achieved using combined
swab results compared with the composite FGS diagnosis (Table 3).
In a secondary analysis of those participants diagnosed with an active schistosome infec-
tion, the sensitivity of PCR from any positive self-collected swab specimen (cervical or vaginal)
against CVL was marginally higher than in the primary analysis, albeit with wide confidence
intervals (Table 4). The gain in sensitivity when evaluating those participants diagnosed with
an active schistosome infection was accompanied by a decline in specificity (Table 4).
Discussion
The BILHIV study is the first to examine the performance of self-collected genital swabs (vaginal
and cervical) for the diagnosis of FGS. Self-collected swabs were compared with provider-
Fig 2. BILHIV study flow diagram. Not visited - the participant was not visited before the study closed for enrollment
(189) Visited but not contacted - a visit was made to the study household, but the participant could not be located (70), had
relocated (39), or died (1) Contacted & not immediately enrolled - (42), out of town (18), declined to participate (60)
Contacted & ineligible - virgin (16), pregnant (17), over 31 (8)
https://doi.org/10.1371/journal.pntd.0008337.g002
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collected CVL, an accepted, non-invasive standard for FGS diagnosis in research settings [12, 14].
The addition of self-collected swabs to CVL increased the number of FGS diagnoses. The sensitiv-
ity of any self-collected genital specimen compared with CVL improved when only those diag-
nosed with an active infection (i.e. positive urine CAA, urine PCR, or urine microscopy) were
considered. Using a composite definition of FGS (any PCR positive genital specimen) as the refer-
ence standard also improved the sensitivity of self-collected genital specimens. In the absence of a
reference standard for FGS [21], the specificity of genital swabs is limited by comparison with
CVL alone. CVL for FGS diagnosis has imperfect sensitivity and may not identify all true posi-
tives. In this analysis, the sensitivity of CVL as the index test compared to self-sampling as the ref-
erence was similar to that of self-sampling as the index test with CVL as reference standard.
A sub-analysis of the BILHIV data also suggests that sensitivity of PCR-based testing of geni-
tal self-samples is high in the subgroup of participants with active infection. The cost of genital
swabs (0.50$/vaginal swab and 0.30$/cervical swab) and molecular testing (6.68$/test) may be
Table 1. Baseline characteristics of 603 Zambian women living in S. haematobium endemic areas near the Zambezi river by district.
Characteristics Overall (n = 603) Community A (n = 319) Community B (n = 284) p-value�
Age in years–Median (IQR) 24 (22–28) 26 (23–29) 24 (21–27) <0.001
Marital Status Single 258 (42.8%) 110 (34.5%) 148 (52.1%) <0.001
Married or Cohabitating 320 (53.1%) 193 (60.5%) 127 (44.7%)
Divorced or Separated 23 (3.8%) 15 (4.7%) 8 (2.8%)
Widowed 2 (0.3%) 1 (0.3%) 1 (0.4%)
Education (highest level) Any Primary School 167 (27.7%) 117 (36.7%) 50 (17.6%) <0.001
Any Secondary School 364 (60.4%) 173 (54.2%) 191 (67.3%)
Training in a Trade 59 (9.8%) 20 (6.3%) 39 (13.7%)
Degree or Higher 3 (0.5%) 3 (0.9%) 0 (0.0%)
None 10 (1.7%) 6 (1.9%) 4 (1.4%)
Employment Status Working 408 (67.7%) 200 (62.7%) 208 (73.2%) 0.006
Not Working 195 (32.3%) 119 (37.3%) 76 (26.8%)
Current Water Contact None 512 (84.9%) 263 (82.5%) 249 (87.7%) 0.02
At Least Weekly 18 (3.0%) 11 (3.5%) 7 (2.5%)
Every 1–2 Months 30 (5.0%) 24 (7.5%) 6 (2.1%)
Every 6–12 Months 43 (7.1%) 21 (6.6%) 22 (7.8%)
Childhood Water Contact None 186 (30.9%) 96 (30.1%) 90 (31.7%) 0.22
At Least Weekly 381 (63.2%) 208 (65.2%) 173 (60.9%)
Every 1–2 Months 24 (4.0%) 12 (3.8%) 12 (4.2%)
Every 6–12 Months 12 (2.0%) 3 (0.9%) 9 (3.2%)
Self-reported History of Schistosomiasis No 572 (94.8%) 294 (92.2%) 278 (97.9%) 0.006
Yes 25 (4.2%) 20 (6.3%) 5 (1.8%)
Maybe 6 (1.0%) 5 (1.6%) 1 (0.4%)
Self- reported Treatment with Praziquantel No 523 (86.7%) 270 (84.6%) 253 (89.1%) 0.11
Yes 61 (10.1%) 40 (12.5%) 21 (7.4%)
Maybe 19 (3.2%) 9 (2.8%) 10 (3.5%)
� comparison of Community-A vs Community-B
https://doi.org/10.1371/journal.pntd.0008337.t001
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affordable in some research settings, but more field-appropriate and scalable NAAT methods
should be investigated. Given the cost of FGS diagnostics, an algorithm which advocates FGS
screening in resource-limited settings among women with positive CAA or urine microscopy
could assist in conserving resources, labour, reagents, and other costs. Applying this algorithm
to the BILHIV study identifies 70.0% of FGS cases identified in a relatively low-prevalence area.
However, an important limitation of restricting genital self-sampling to a sub-group with active
infection is a decreased ability to detect FGS cases in the population, as FGS would not be iden-
tified in women without active infection. This decrement in the overall sensitivity of screening
must be balanced against the availability of resources. Other practical limitations to this strategy
include low prevalence populations, the imperfect sensitivity of Schistosoma PCR in genital self-
sampling, and the current availability of PCR and CAA as research tools that do not yet allow
individual rapid diagnosis at the point-of-care [35]. To maximally leverage resources, FGS self-
sampling would be integrated into other reproductive health platforms, ideally those that also
utilize self-sampling in the diagnosis of reproductive tract infections, such as HPV [22, 25].
Table 2. Diagnostic test results and FGS prevalence in 603 Zambian women living in S. haematobium endemic areas near the Zambezi river.
Characteristics Overall (n = 603)
% (n)
Community-A (n = 319)
% (n)
Community-B (n = 284)
% (n)
p-value
Hematuria 28.7 (173) 31.0 (99) 26.1 (74) 0.2
Urine Microscopy 5.5 (33/603) 8.2 (26/319) 2.5 (7/284) 0.002
Median egg count per 15mL‡ 18 17.5 18
IQR 5–35 5–35 8–90
Urine CAA� 15.1 (91/601) 20.5 (65/317) 9.2 (26/284) <0.001
Median pg/mL‡ 9.10 11.46 5.93
IQR 2.2–58.6 2.3–42.1 2.2–112.0
Urine PCR� 4.3 (26/601) 6.3 (20/317) 2.1 (6/284) 0.012
Median Ct‡ 29.6 30.2 29.3
IQR 27.8–33.5 26.4–34.9 29.0–32.7
Active schistosome Infection�
[any urine test positive]
15.6 (94/601) 21.1 (67/317) 9.5 (27/284) <0.001
PCR–CVL† 2.7 (14/527) 3.8 (11/290) 1.3 (3/237) 0.06��
Median Ct‡ 34.6 35.3 33.2
IQR 33.0–37.0 33.0–37.0 21.0–38.0
PCR–Cervical Swab 3.3 (20/603) 4.4 (14/319) 2.1 (6/284) 0.12
Median Ct‡ 35.3 35.8 33.3
IQR 29.6–37.1 29.4–37.2 29.7–36.3
PCR–Vaginal Swab 2.5 (15/603) 2.5 (8/319) 2.5 (7/284) 0.97
Median Ct‡ 34.3 35.4 32.2
IQR 23.6–37.1 30.6–37.2 23.2–35.2
Any PCR Positive Sample†† 5.7 (30/529) 7.6 (22/291) 3.4 (8/238) 0.02
PCR positive–Vaginal or Cervical Swab 4.0 (24/603) 5.3 (17/319) 2.5 (7/284) 0.07
�2 urine vials arrived at LUMC empty (n = 601)
�� Calculated by Fisher’s exact (otherwise by chi-squared)
† 527 women presented for CVL– 290 Community-A and 237 Community-B
‡ Median egg count, CAA concentrations and PCR Ct-value restricted to positive tests
††One participant from each of Site-1 and Site-2 had positive self-collected PCR specimens but did not present to clinic (n = 529)
Abbreviations: CAA—Circulating Anodic Antigen, CVL–Cervicovaginal Lavage, PCR–Polymerase Chain Reaction for the detection of Schistosoma DNA
https://doi.org/10.1371/journal.pntd.0008337.t002
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Fig 3. Distribution of positive diagnostic test results by age group. A. Distribution of positive urine CAA, urine
microscopy, and urine PCR results by age group
�
B. Distribution of positive genital PCR results by age group
�
C.
Distribution of any positive genital PCR result by age group� �Please see S1 Table for further details of the numbers
of women tested per time point
https://doi.org/10.1371/journal.pntd.0008337.g003
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Scalable, affordable, and field-acceptable diagnostics are necessary to improve our understand-
ing of the current population prevalence of FGS and to limit the negative health impact of HIV-1,
infertility, and gynaecologic symptoms. After repeated fresh-water exposures, girls living in
endemic areas may develop the genital changes associated with FGS prior to sexual debut or the
onset of menstruation [36]. A single dose treatment of praziquantel will decrease egg production.
but will only kill a proportion of living schistosomes [3]. Data on the effect of praziquantel treat-
ment in FGS are limited, with small numbers and heterogeneous methods, but do suggest a pro-
portion of FGS lesions remain despite praziquantel treatment [37–39]. Thus, early identification of
FGS and subsequent praziquantel treatment prior to the age of 21 is associated with beneficial out-
comes, such as lower prevalence of contact bleeding, lower odds of sandy patches [40], and lower
rates of sub-fertility [41]. Prevention efforts cannot be underestimated, and young women should
be prioritized to obtain the maximum benefit from the roll-out of FGS diagnosis and treatment.
To date, no previous studies of FGS diagnostics have used CVL as a reference standard and
cross-study comparisons are limited due to heterogeneity of methods [8, 12, 14, 21]. Previously
published work has reported low sensitivity and high specificity of Schistosoma CVL PCR for
FGS diagnosis in African populations [8, 14, 21]. In adult Zimbabwean women (ages 15–49),
CVL PCR sensitivity was 53% and specificity 79% compared with cervical visualization and
histopathology [14]. The study had some limitations relating to loss of specimens due to cold
chain malfunctions, and extended specimen storage time (10 years), potentially affecting PCR
outcomes. In an adolescent South African population (age range 15–23), CVL PCR was com-
pared with urine microscopy, cervical visualization, and urogenital symptoms by latent class
analysis with a sensitivity of 52.4% (33.2–73.6) and specificity of 42.4% (37.9–47.0) [21].
Fig 4. Venn Diagram of 28� Positive PCR-based Self-Collected Specimens (paired with CVL) for Schistosoma by
Collection Type �2 participants with positive genital self-collected specimens did not follow up in clinic for
cervicovaginal lavage.
https://doi.org/10.1371/journal.pntd.0008337.g004
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Together, these studies further illustrate the limited performance of Schistosoma PCR in the
absence of a reliable FGS reference standard [15].
The performance of diagnostic tests for schistosome infection can vary by background par-
asite prevalence [42]. Important information regarding disease stage, intensity and morbidity
may be missed in the absence of appropriate diagnostics [31]. No one test captures all charac-
teristics of infection simultaneously and with perfect sensitivity. Conventional diagnostic tests
(reagent strips and urine microscopy) are insensitive, especially in low-prevalence areas, where
light intensity infections can be underestimated [42]. The overall prevalence of schistosome
infection in our study population was 5.5% by single urine microscopy, meeting the WHO
classification of a low-risk community [43]. Egg detection in urine microscopy may increase
slightly with serial urine collections [7, 44]. The prevalence of FGS, as diagnosed by a positive
PCR in any genital specimen, was 5.0% with site variations (2.8%-6.9%). Our study took place
in two communities within Livingstone. Community-A is closer to a water source and women
in Community-A had a higher overall prevalence of schistosome infection and FGS. The sensi-
tivity of microscopy, urine PCR, and CAA diminish in areas of low parasite prevalence [42], or
after treatment with praziquantel [44]. Sensitivity of CAA can be increased by using a larger
sample volume [45]. Our results confirm previous findings that urine CAA has higher sensitiv-
ity than microscopy in low-endemic settings [42] and further illustrates that schistosome infec-
tion is focal and prevalence can vary within neighbouring communities.
When comparing the performance of sampling techniques for parasite DNA retrieval, cer-
vical swabs detected 5 cases of FGS not detected by vaginal swabs and CVL. This was also true
Table 3. Sensitivity and specificity of genital specimens for the detection of Schistosoma DNA by PCR.
Reference Standard Index test Sensitivity (%) Specificity (%)
Cervicovaginal lavage PCR Vaginal swab PCR 35.7 [5/14]
(12.8–64.9)
98.2 [504/513]
(96.7–99.2)
Cervical swab PCR 42.9 [6/14]
(17.7–71.1)
97.7 [501/513]
(95.9–98.8)
Vaginal or Cervical Swab PCR 57.1 [8/14]
(28.9–82.3)
97.3 [499/513]
(95.5–98.5)
Cervical swab PCR Cervicovaginal Lavage PCR 33.3 [6/18]
(13.3–59.0)
98.4 [501/509]
(96.9–99.3)
Vaginal Swab PCR 55.0 [11/20]
(31.5–76.9)
99.3 [579/583]
(98.3–99.8)
Vaginal Swab PCR Cervicovaginal Lavage PCR 35.7 [5/14]
(12.8–64.9)
98.2 [504/513]
(96.7–99.2)
Cervical Swab PCR 73.3 [11/15]
(44.9–92.2)
98.5 [579/588]
(97.1–99.3)
Vaginal or Cervical Swab PCR Cervicovaginal Lavage PCR 36.4 [8/22]
(17.2–59.3)
98.8 [499/505]
(97.4–99.6)
Composite FGS Diagnosis� Vaginal swab PCR 50.0 [15/30]
(31.3–68.7)
100.0 [499/499]
(99.3–100.0)
Cervical swab PCR 66.7 [20/30]
(47.2–82.7)
100.0 [499/499]
(99.3–100.0)
Vaginal or Cervical Swab PCR 80.0 [24/30]
(61.4–92.3)
100.0 [499/499]
(99.3–100.0)
Cervicovaginal Lavage PCR 50.0 [14/28]
(30.6–69.4)
100.0 [499/499]
(99.3–100.0)
Abbreviations: CAA–Circulating Anodic Antigen, CS–Cervical Swab, CVL–Cervicovaginal Lavage, PCR–Polymerase Chain Reaction for the detection of Schistosoma
DNA, VS–Vaginal Swab
�Composite FGS Diagnosis–any positive PCR result on a genital specimen (CVL, vaginal swab or cervical swab)
https://doi.org/10.1371/journal.pntd.0008337.t003
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for vaginal swabs (2 FGS cases) and CVL (6 FGS cases) that were not detected in other sites
examined by PCR-based methods (Fig 4). In the absence of self-collecting cervical cytology, it
is not possible to confirm if the participants self-sampled from the cervix. However, the longer
swab and collection techniques likely allowed a high cervicovaginal specimen that contributed
to a greater number of PCR positive samples than vaginal swabs. Studies of FGS histopathol-
ogy report the most common location for egg deposition is the cervix [6], which may explain
the higher proportion of positive specimens in specimens detecting DNA from this site. Geni-
tal swabs are also field-appropriate, acceptable to participants, and scalable, while CVL
requires vaginal speculum insertion and is performed by trained health workers.
The BILHIV study was conducted in a low prevalence area, therefore the presented esti-
mates of sensitivity are subject to a high degree of imprecision due to the small numbers of
total FGS cases. There was excellent retention with 87.4% (527/603) of participants presenting
to the clinic for CVL, with very little missing data. The women self-collected vaginal and cervi-
cal specimens privately in their own homes. This raises the question of false negative genital
swabs, which could be addressed by measuring B-globin PCR as a positive control to confirm
the presence of human DNA [22]. BILHIV data confirm previous findings that Schistosoma
DNA can be detected in the genital tract in the absence of egg excretion [7, 8], and in partici-
pants with negative CAA. While these specimens may appear as false positives, the reported
specificity of PCR for detecting Schistosoma DNA is near 100% [14, 21]. S. haematobium eggs
Table 4. Sub-analysis of sensitivity and specificity of self-collected genital swabs compared with cervicovaginal lavage for the detection of Schistosoma DNA in par-
ticipants with positive urine specimens: CAA(n = 78), microscopy (n = 32), PCR (n = 26).
Reference test Index test Sensitivity (%) Specificity (%)
Urine CAA
Cervicovaginal lavage PCR
Vaginal swab PCR 50.0 [4/8]
(15.7–84.3)
90.0 [63/70]
(80.5–95.9)
Cervical swab PCR 62.5 [5/8]
(24.5–91.5)
87.1 [61/70]
(77.0–93.9)
Vaginal or cervical swab PCR 87.5 [7/8]
(47.3–99.7)
85.7 [60/70]
(75.3–92.9)
Urine Microscopy
Cervicovaginal lavage PCR Vaginal swab PCR 55.6 [5/9]
(21.2–86.3)
73.9 [17/23]
(51.6–89.3)
Cervical swab PCR 66.7 [6/9]
(29.9–92.5)
56.5 [13/23]
(34.5–76.8)
Vaginal or cervical swab PCR 88.9 [8/9]
(51.8–99.7)
56.5 [13/23]
(34.5–76.8)
Urine PCR
Cervicovaginal lavage PCR Vaginal swab PCR 55.6 [5/9]
(21.2–86.3)
70.6 [12/17]
(44.0–89.7)
Cervical swab PCR 66.7 [6/9]
(29.9–92.5)
47.1 [8/17]
(23.0–72.2)
Vaginal or cervical swab PCR 88.9 [8/9]
(51.8–99.7)
47.1 ([8/17]
23.0–72.2)
Active Schistosome Infection (Urine positive for PCR, CAA, or Microscopy)
Cervicovaginal lavage PCR Vaginal swab PCR 55.6 [5/9]
(21.2–86.3)
90.3 [65/72]
(81.0–96.0)
Cervical swab PCR 66.7 [6/9]
(29.9–92.5)
86.1 [62/72]
(75.9–93.1)
Vaginal or cervical swab PCR 88.9 [8/9]
(51.8–99.7)
84.7 [61/72]
(74.3–92.1)
https://doi.org/10.1371/journal.pntd.0008337.t004
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can be detected in semen [46] and our study did not objectively evaluate for PSA or other
markers of recent sexual contact.
Overall, the relatively high concordance of DNA detection in genital self-collected speci-
mens and CVL suggest that self-collection methods for the diagnosis of FGS are feasible in
resource limited areas. Drawing on the experience of HPV, self-sampling has been shown to
be scalable and effective in real-world settings [47]. As the focus in schistosomiasis shifts from
morbidity control to elimination, data on the performance of diagnostic tests for infection and
morbidity in low-prevalence settings becomes increasingly applicable [48]. To achieve elimina-
tion of both infection and chronic disease such as FGS, low-prevalence areas require novel and
innovative interventions and diagnostic strategies to provide site-appropriate, accurate preva-
lence estimates [48].
Conclusion
Genital self-sampling increased the overall number of PCR-based FGS diagnoses in a field set-
ting, compared with cervicovaginal lavage. Schistosomiasis is focal and background parasite
prevalence may impact test sensitivity. Home-based self-sampling may represent a scalable
alternative method for FGS community-based diagnosis in endemic resource limited setting.
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